The recent emergence of antibody (Ab)-mediated pure red cell aplasia (PRCA) resulting from administration of certain erythropoiesis-stimulating agents (ESAs) has heightened awareness of the potential for this disorder in patients receiving ESAs for anaemia associated with chronic kidney disease (CKD). The Spanish Society of Nephrology sponsored an independent registry for analysis of patients who developed epoetin-induced, Ab-mediated PRCA in Spain. Twelve patients from 11 regional hospitals were included in the Spanish PRCA registry from November 2000 to December 2002 that met the criteria for Ab-mediated PRCA. Patients were reported using a standardized form specifically developed for PRCA, and serum samples were analysed in a central laboratory at Reina Sofia University Hospital in Cordoba, Spain. The characteristics of these patients, their serological and haematological results, and the outcomes of immunosuppressive therapies are presented. The Spanish PRCA registry serves as a model for establishing an independent global PRCA registry sponsored by the various nephrology societies in European Union countries, and elsewhere and coordinated by key investigators from the respective countries.
Introduction
Cases of antibody (Ab)-mediated pure red cell aplasia (PRCA) have been reported to manufacturers of erythropoiesis-stimulating agents (ESAs) and national health authorities through existing pharmacovigilance programmes in various countries, but an independent global case registry for Ab-mediated PRCA does not exist. Consequently, the reporting and serological analysis of cases have not been done in a systematic and uniform manner across countries, or under the sponsorship of a national nephrology society within each country.
This report summarizes the recent retrospective analysis of cases of Ab-mediated PRCA in Spain under the auspices of the Spanish Society for Nephrology. This case series of 12 patients with epoetin-induced PRCA is unique in its systematic collection of case histories from regional clinics and hospitals into an independent, society-sponsored registry, and the uniform serological analysis of the patients' serum samples in a central laboratory facility. In addition, the results of immunosuppressive therapy for PRCA in these patients are presented and discussed. Together, these facets of the Spanish experience with Ab-mediated PRCA represent a model for the reporting and analysis of similar cases in other European countries and elsewhere through an independent global PRCA case registry. The aims of this global PRCA registry are to collect and analyse new cases as they occur, to analyse previous cases retrospectively under standardized criteria, and to study the clinical sequelae to Ab-mediated PRCA and their treatment.
Spanish case series of Ab-mediated PRCA [1, 2] .
Reporting of cases
Serological analysis for anti-EPO Abs was performed at the research laboratory of the Reina Sofia University Hospital in Cordoba. Antibodies were assayed by the RIP assay for quantifying anti-EPO binding Abs and by the UT-7 cell line bioassay for quantifying levels of EPO-neutralizing Abs [3] . Results from the RIP assay were expressed as the IP 50 titres, which represent 50% of the total precipitable radioactivity counts in a series of serum dilutions titrated against a standard amount of 125 I-labelled EPO. This RIP end-point is different from the end-point values described by Casadevall and colleagues, which were expressed as the total international units (IU) of EPO that can be neutralized by Abs in 1 ml of serum [4] . A bioassay for Ab-mediated inhibition of bone marrow erythroid cells (i.e. erythroid colony assay) was not performed because of lack of sufficient serum samples.
Patient characteristics and results of Ab assays
The baseline demographic and clinical characteristics of patients are shown in Table 1 . In general, these patients were older (61±21 years of age; range 22-82), males with chronic kidney disease (CKD) from one of several causes including diabetes (n ¼ 3), tubulointerstitial disease (n ¼ 3), glomerular disease (n ¼ 3) or unknown aetiology (n ¼ 3). Almost all patients had co-morbidities including hypertension (n ¼ 11), diabetes (n ¼ 4), cardiovascular disease (n ¼ 7) or malignancy (n ¼ 1). Seven of the 12 patients were receiving haemodialysis, three received peritoneal dialysis and two were pre-dialysis patients. All but one patient received epoetin-a (Eprex Õ Ortho Biotech, LLC, Manati, Puerto Rico) by the subcutaneous (s.c.) route either given alone (n ¼ 9) or in combination with epoetin-b (NeoRecormon Õ , Roche Pharmaceuticals, Mannheim, Germany) (n ¼ 1) or darbepoetin-a (Aranesp Õ , Amgen Inc., Thousand Oaks, CA), (n ¼ 1); one patient received only epoetin-b. Patients received treatments over an average of 53±34 months (range: 21-137), but the time to onset of PRCA was shorter, at an average of 15.6±4.4 months (range: 3-24). This time to onset of PRCA is longer than the 9 month average treatment period reported in other studies [1, 2] .
All 12 patients were seronegative for HBsAg, human HIV and human parvovirus B19; 11 patients were seronegative for anti-HCV Abs (Table 1) . No other root causes of PRCA other than treatment with epoetin were identified. The patients' average serum ferritin levels were elevated at an average of 561±412 mg/l. One month prior to the diagnosis of refractory anaemia, the average haemoglobin (Hb) level was 9.1±2.6 g/dl. All patients' blood reticulocyte counts were <10 000/mm 3 and accounted for only 0.68±0.82% of the total cellularity; counts of white blood cells (8050± 3 600/mm 3 ) and platelets (169 417±57 897/mm 3 ) were normal. The results of bone marrow aspirates or biopsies confirmed the diagnosis of Ab-mediated PRCA in all 12 patients. Results of the RIP assay showed that eight patients were positive for precipitating, anti-epoetin Abs ( Table 2 ). The RIP titres in these eight sera, expressed as 50% of the total serum-precipitable counts of 125 I-labelled EPO (IP 50 counts per minute, c.p.m.), ranged from 2265 to 57 705 c.p.m., with an average titre of 20 687±6704 c.p.m.. These titres corresponded roughly, but were not identical, to the RIP titres obtained in Dr Casadevall's laboratory using the assay end-point of number of IU of EPO neutralized by serum Abs. Sera from five of these 12 patients contained EPO-neutralizing Abs that inhibited the proliferation of EPO-dependent UT-7 by 25-75%.
Antibody titres obtained with the RIP assay did not correspond completely with the results of the bioassay for EPO-neutralizing Abs. As shown in Table 2 , the bioassay was less sensitive than RIP in detecting EPO-specific Abs in three sera (patient numbers 2, 3 and 6). However, these results may reflect the different nature of Abs measured with bioassay (i.e. EPOneutralizing Abs) versus RIP (i.e. EPO-binding Abs). For example, serum from patient 3 had an RIP titre of 9857 c.p.m., but no detectable EPO-neutralizing Abs, while serum from patient 4 had an RIP titre of 4940 c.p.m., yet effectively neutralized 25% of exogenous EPO in the bioassay (Table 2) . A summary of the results of these two assays is presented in Table 3 , which compares the titres in Ab-positive sera with titres observed in Ab-negative sera.
Therapy for Ab-mediated PRCA
In all patients, erythropoietic treatment was halted and immunosuppressive therapy was initiated after diagnosis of PRCA. Immunosuppressive therapy consisted of corticosteroids alone (nine patients), corticosteroids plus immunoglobulin (one patient), corticosteroids plus nandrolone (one patient) and corticosteroids plus a kidney transplant (one patient). Patients were transfused with an average of 11.0±8.1 (range 0-20) units of blood.
As of September 2003, Hb levels had returned to 10 g/dl (average), and five patients had recovered including four of the nine patients (44.4%) who received corticosteroid therapy alone and the single kidney transplant patient (Table 4) . Three patients have remained anaemic, and four have died. These results compare well with results from a previous study by Verhelst and colleagues, who achieved a 56% recovery rate (10 of 18 patients) from Ab-mediated PRCA using corticosteroid therapy alone [5] .
Discussion of Spanish case series
A historic perspective of the recent increase in global cases of Ab-mediated PRCA suggests that the creation of an independent, centralized global PRCA registry would foster the comparative analysis of cases compiled from the various national pharmacovigilance registries. For those patients who received some type of immunosuppressive or depletion (e.g. intravenous Ig or plasma exchange) therapy, such an independent registry may have expedited consensus opinion on standard diagnostic criteria for epoetin-induced PRCA and optimal therapeutic regimens for this disorder.
We investigated PRCA that occurred during epoetin treatment of CKD-associated anaemia in 12 Spanish patients. After an initial response to EPO treatment, Bioassay titre ¼ percentage inhibition of EPO-stimulated UT-7 cell proliferation, measured by cellular uptake of tritiated thymidine in the presence of 1 ml of PRCA serum, compared with control (nonimmune) human serum. Mean serum RIP titres are expressed as 50% of the total amount of radiolabelled rHuEPO (in c.p.m.) precipitated by 1 ml of patient's serum±SEM.
b
Bioassay titre is expressed as the percentage inhibition of EPOstimulated UT-7 cell proliferation, measured by cellular uptake of tritiated thymidine in the presence of 1 ml of PRCA serum, compared with control (non-immune) human serum. these patients became markedly anaemic and required continued red blood cell transfusions. Subsequent bone marrow examinations confirmed the diagnosis of PRCA in 12 patients, and epoetin-binding Abs were detected in eight of the 12 patients by RIP assay. Epoetin-neutralizing Abs were detected by bioassay in five patients. The data presented in this report underscore the utility of testing groups of sera in the same laboratory, using the same reagents and assay procedures to ensure comparability among samples. These data also point to the differences in the way Ab titres are expressed (e.g. the RIP titres presented in this study vs previous studies with RIP), even with use of the same assay procedure employed in other laboratories [2, 6] . Standardized Ab assay procedures and recommendations for interpretation of results would be helpful for establishing uniform serodiagnostic criteria in any laboratory and for the purposes of reporting results to an independent registry for PRCA.
The present case series of Ab-mediated PRCA in Spain serves as a prototype for collection and analysis of similar cases emerging globally and in various European countries. In addition to the standard case report form, the Spanish Society of Nephrology also alerted physicians of the characteristics of Ab-mediated PRCA in a society newsletter and an operational registry website. The collection and analysis of global PRCA cases could be accomplished in a similar manner through an established independent global PRCA case registry that would be sponsored by national nephrology societies under the administrative management and scientific support of leading researchers from their respective countries.
Because the majority of cases of epoetin-induced PRCA occurred in Europe, the resulting increased awareness of and concern with this disorder has resulted in the inclusion of this potential problem in the recently revised EBPG published in 2004.
Conclusions
The successful use of recombinant ESAs for treatment of renal anaemia was unblemished until the recent emergence of cases of Ab-mediated PRCA in patients treated with one formulation of epoetin-a outside of the USA. Previous cases of epoetin-induced PRCA were reported sporadically through electronic website alerts from manufacturers and individually published case studies. Thus, because of the protracted onset of disease in some patients or delayed diagnosis in various settings using different diagnostic criteria that affected timely reporting, a clear picture was not easily obtained of the temporal emergence of cases and their characteristics. These factors were complicated further by the lack of a centralized, independent registry for PRCA cases and analysis in either individual countries or worldwide.
The Spanish case series of Ab-mediated PRCA presented here may serve as a model system for reporting cases and analysing patients' serum for the presence of anti-EPO Abs in a uniform manner using standardized inclusion criteria and a serodiagnostic method. Collection and analysis of data from patients with Ab-mediated PRCA could be done most effectively through an independent global PRCA registry that focuses its efforts specifically toward characterizing the risks factors for and clinical course of this disorder, and the outcomes of various immunosuppressive therapies. In addition, the present case series also provides important information on the outcomes of therapy for epoetin-induced PRCA. These latter findings corroborate the results of other studies showing that certain immunosuppressive therapies correct the severe anaemia associated with PRCA and that therapeutic intervention is required for patients with this disorder.
Because the development of neutralizing Abs is possible with the use of any recombinant therapeutic protein, clinicians should be vigilant in monitoring for the development of Abs in patients receiving recombinant proteins. Monitoring of immunological safety will become an increasingly important part of the clinical development programme of biopharmaceutical products, including next generation products and biosimilar versions of existing products. For patients who develop Ab-mediated PRCA, the development of an optimal therapy protocol also remains an important goal.
